STOCK TITAN

Ocular Therapeutix Inc - OCUL STOCK NEWS

Welcome to our dedicated news page for Ocular Therapeutix (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeutix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ocular Therapeutix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ocular Therapeutix's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.4%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.99%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.99%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.37%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.33%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
conferences earnings
Ocular Therapeutix Inc

Nasdaq:OCUL

OCUL Rankings

OCUL Stock Data

1.35B
128.47M
3.68%
50.11%
6.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bedford

About OCUL

ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib